← All trials
NCT04406415
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2020
- Primary completion
- Aug 31, 2020
- Completion date
- Oct 31, 2020
- First posted
- May 28, 2020
- Last posted
- May 28, 2020
- Enrollment
- 20
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ensysce BiosciencesLead sponsor
- National Institute on Drug Abuse (NIDA)Collaborator
- Ensysce BiosciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.